Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16699602 | 0.93 | SMN1; SMN2 (0.39) | KMT2AMEN1ALDH1A1TSHRALOX15 | |
| SCHEMBL17444067 | 0.90 | MAPK1 (0.33) | KMT2AMEN1ALDH1A1TSHRALOX15 | |
| SCHEMBL19169756 | 0.89 | KMT2A (0.32) | KMT2AMEN1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL745218 | 0.88 | OPRM1 (0.46) | KMT2AMEN1ALDH1A1TSHRALOX15 | |
| SCHEMBL10263 | 0.87 | ALDH1A1 (0.38) | KMT2AMEN1ALDH1A1TSHRPOLB | |
| SCHEMBL24515538 | 0.87 | ALDH1A1 (0.34) | KMT2AMEN1ALDH1A1TSHRPOLB | |
| SCHEMBL12529117 | 0.87 | KDM4E (0.36) | KMT2AMEN1ALDH1A1TSHRPOLB | |
| SCHEMBL17611838 | 0.84 | MAPK1 (0.31) | ALDH1A1MAPK1 | |
| SCHEMBL22034866 | 0.82 | POLB (0.35) | KMT2AMEN1ALDH1A1TSHRPOLB | |
| SCHEMBL25281621 | 0.80 | CYP4F2 (0.44) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591328-B2 | Highly active CSF1R inhibitor compound | XIAMEN BIOTIME BIOTECHNOLOGY CO., LTD. (CN) | 2023-02-28 | — | — | US | disclosed |
| US-20200399265-A1 | HIGHLY ACTIVE CSF1R INHIBITOR COMPOUND | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2020-12-24 | — | — | US | disclosed |
| EP-3744718-A1 | HIGHLY ACTIVE CSF1R INHIBITOR COMPOUND | Adlai Nortye Biopharma Co., Ltd. (CN) | 2020-12-02 | — | — | EP | disclosed |
| US-9150577-B2 | Heterocyclic compounds containing an indole core | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| US-9150577-B2 | Heterocyclic compounds containing an indole core | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| US-20130109679-A1 | HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-02 | — | — | US | disclosed |
| US-20130109679-A1 | HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-02 | — | — | US | disclosed |
| EP-2509980-A1 | HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE | Boehringer Ingelheim International GmbH (DE) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011071716-A1 | HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011071716-A1 | HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109679-A1 | HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE | BRSK2, RPS6KA2, RPS6KB2 | KMT2A 3498/4885MEN1 3774/4885ALDH1A1 3766/4885 |
| US-11591328-B2 | Highly active CSF1R inhibitor compound | CSF1R, CSF3R, CD209 | KMT2A 469/4885MEN1 492/4885ALDH1A1 2363/4885 |
| US-20200399265-A1 | HIGHLY ACTIVE CSF1R INHIBITOR COMPOUND | CSF1R, CSF3R, CD209 | KMT2A 469/4885MEN1 492/4885ALDH1A1 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.